变构和正构表皮生长因子受体抑制剂联合治疗非小细胞肺癌
Combination of Allosteric and Orthosteric EGFR Inhibitors for Treating Non-Small-Cell Lung Cancer.
作者信息
Sabnis Ram W
机构信息
Smith, Gambrell & Russell LL, 1105 W. Peachtree Street NE, Suite 1000, Atlanta, Georgia 30309, United States.
出版信息
ACS Med Chem Lett. 2024 Feb 27;15(3):342-343. doi: 10.1021/acsmedchemlett.4c00076. eCollection 2024 Mar 14.
Abstract
Provided herein are novel combination of allosteric and orthosteric EGFR inhibitors, pharmaceutical compositions, use of such compounds in treating non-small-cell lung cancer, and processes for preparing such compounds.
摘要
本文提供了变构和正构表皮生长因子受体（EGFR）抑制剂的新型组合、药物组合物、此类化合物在治疗非小细胞肺癌中的用途以及制备此类化合物的方法。
相似文献
1
Combination of Allosteric and Orthosteric EGFR Inhibitors for Treating Non-Small-Cell Lung Cancer.
ACS Med Chem Lett. 2024 Feb 27;15(3):342-343. doi: 10.1021/acsmedchemlett.4c00076. eCollection 2024 Mar 14.
2
Systematic analysis and molecular profiling of EGFR allosteric inhibitor cross-reactivity across the proto-oncogenic ErbB family kinases by integrating dynamics simulation, energetics calculation and biochemical assay.
Eur Biophys J. 2022 Apr;51(3):283-295. doi: 10.1007/s00249-022-01594-0. Epub 2022 Mar 21.
3
In Silico Identification of 2,4-Diaryl-6-styrylpyridine Derivatives as Orthosteric-Allosteric EGFR Inhibitors.
Curr Comput Aided Drug Des. 2025 Apr 29. doi: 10.2174/0115734099370189250416024026.
4
Design, synthesis and biological evaluation of EGFR kinase inhibitors that spans the orthosteric and allosteric sites.
Bioorg Med Chem. 2023 Dec 15;96:117534. doi: 10.1016/j.bmc.2023.117534. Epub 2023 Nov 10.
5
Novel KRAS Inhibitors for Treating Non-Small-Cell Lung Cancer.
ACS Med Chem Lett. 2024 May 22;15(6):773-774. doi: 10.1021/acsmedchemlett.4c00217. eCollection 2024 Jun 13.
6
Novel KRAS Inhibitors for Treating Non-small Cell Lung Cancer.
ACS Med Chem Lett. 2024 Jul 25;15(8):1201-1202. doi: 10.1021/acsmedchemlett.4c00342. eCollection 2024 Aug 8.
7
Novel 1,6-Naphthridine Compounds as SMARCA2 Inhibitors for Treating Non-small Cell Lung Cancer.
ACS Med Chem Lett. 2025 Feb 14;16(3):371-372. doi: 10.1021/acsmedchemlett.5c00048. eCollection 2025 Mar 13.
8
1,6-Naphthridine Compounds as SMARCA2 Inhibitors for Treating Non-small Cell Lung Cancer.
ACS Med Chem Lett. 2025 Mar 20;16(4):528-529. doi: 10.1021/acsmedchemlett.5c00128. eCollection 2025 Apr 10.
9
Discovery of Novel Allosteric EGFR L858R Inhibitors for the Treatment of Non-Small-Cell Lung Cancer as a Single Agent or in Combination with Osimertinib.
J Med Chem. 2022 Oct 13;65(19):13052-13073. doi: 10.1021/acs.jmedchem.2c00893. Epub 2022 Sep 30.
10
Harnessing the druggability at orthosteric and allosteric sites of PD-1 for small molecule discovery by an integrated in silico pipeline.
Comput Biol Chem. 2023 Dec;107:107965. doi: 10.1016/j.compbiolchem.2023.107965. Epub 2023 Sep 27.
本文引用的文献
1
Pitfalls and Considerations in Determining the Potency and Mutant Selectivity of Covalent Epidermal Growth Factor Receptor Inhibitors.
J Med Chem. 2024 Jan 11;67(1):2-16. doi: 10.1021/acs.jmedchem.3c01502. Epub 2023 Dec 22.
2
Targeted treatment for unresectable EGFR mutation-positive stage III non-small cell lung cancer: Emerging evidence and future perspectives.
Lung Cancer. 2024 Jan;187:107414. doi: 10.1016/j.lungcan.2023.107414. Epub 2023 Nov 8.
3
Therapeutic role of EGFR - Tyrosine kinase inhibitors in non-small cell lung cancer with leptomeningeal metastasis.
Transl Oncol. 2024 Jan;39:101832. doi: 10.1016/j.tranon.2023.101832. Epub 2023 Nov 25.
4
The efficacy and safety of immune checkpoint inhibitors for patients with EGFR-mutated non-small cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy: A systematic review and network meta-analysis.
Cancer Med. 2023 Sep;12(18):18516-18530. doi: 10.1002/cam4.6453. Epub 2023 Aug 16.
5
Targeted therapy for lung cancer: Beyond EGFR and ALK.
Cancer. 2023 Jun 15;129(12):1803-1820. doi: 10.1002/cncr.34757. Epub 2023 Apr 19.
6
Amivantamab, an Epidermal Growth Factor Receptor (EGFR) and Mesenchymal-epithelial Transition Factor (MET) Bispecific Antibody, Designed to Enable Multiple Mechanisms of Action and Broad Clinical Applications.
Clin Lung Cancer. 2023 Mar;24(2):89-97. doi: 10.1016/j.cllc.2022.11.004. Epub 2022 Nov 11.
Zotero 插件